Ileitis Secondary to Oral Capecitabine Treatment?

The efficacy of capecitabine as adjuvant therapy in colon cancer is well demonstrated and its lower toxicity rates when compared with 5-FU make it an increasingly more favourable option for patients. This case highlights the awareness of a potentially severe side effect related to the use of capecit...

Descripción completa

Detalles Bibliográficos
Autores principales: Radwan, Rami, Namelo, Wanangwa C., Robinson, Mark, Brewster, Alison E., Williams, Gethin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522479/
https://www.ncbi.nlm.nih.gov/pubmed/23251164
http://dx.doi.org/10.1155/2012/154981
_version_ 1782253075056033792
author Radwan, Rami
Namelo, Wanangwa C.
Robinson, Mark
Brewster, Alison E.
Williams, Gethin L.
author_facet Radwan, Rami
Namelo, Wanangwa C.
Robinson, Mark
Brewster, Alison E.
Williams, Gethin L.
author_sort Radwan, Rami
collection PubMed
description The efficacy of capecitabine as adjuvant therapy in colon cancer is well demonstrated and its lower toxicity rates when compared with 5-FU make it an increasingly more favourable option for patients. This case highlights the awareness of a potentially severe side effect related to the use of capecitabine, yet through the early identification of symptoms patients can be managed conservatively.
format Online
Article
Text
id pubmed-3522479
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35224792012-12-18 Ileitis Secondary to Oral Capecitabine Treatment? Radwan, Rami Namelo, Wanangwa C. Robinson, Mark Brewster, Alison E. Williams, Gethin L. Case Rep Med Case Report The efficacy of capecitabine as adjuvant therapy in colon cancer is well demonstrated and its lower toxicity rates when compared with 5-FU make it an increasingly more favourable option for patients. This case highlights the awareness of a potentially severe side effect related to the use of capecitabine, yet through the early identification of symptoms patients can be managed conservatively. Hindawi Publishing Corporation 2012 2012-11-26 /pmc/articles/PMC3522479/ /pubmed/23251164 http://dx.doi.org/10.1155/2012/154981 Text en Copyright © 2012 Rami Radwan et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Radwan, Rami
Namelo, Wanangwa C.
Robinson, Mark
Brewster, Alison E.
Williams, Gethin L.
Ileitis Secondary to Oral Capecitabine Treatment?
title Ileitis Secondary to Oral Capecitabine Treatment?
title_full Ileitis Secondary to Oral Capecitabine Treatment?
title_fullStr Ileitis Secondary to Oral Capecitabine Treatment?
title_full_unstemmed Ileitis Secondary to Oral Capecitabine Treatment?
title_short Ileitis Secondary to Oral Capecitabine Treatment?
title_sort ileitis secondary to oral capecitabine treatment?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522479/
https://www.ncbi.nlm.nih.gov/pubmed/23251164
http://dx.doi.org/10.1155/2012/154981
work_keys_str_mv AT radwanrami ileitissecondarytooralcapecitabinetreatment
AT namelowanangwac ileitissecondarytooralcapecitabinetreatment
AT robinsonmark ileitissecondarytooralcapecitabinetreatment
AT brewsteralisone ileitissecondarytooralcapecitabinetreatment
AT williamsgethinl ileitissecondarytooralcapecitabinetreatment

Ejemplares similares